Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
PurposeMolecular profiling is crucial in naïve non-small cell lung cancer (NSCLC). While tissue-based analysis is challenged by turnaround time and scarcity of tissue, there is increasing demand for liquid biopsy. We aimed to analyze the use of upfront liquid biopsy as a molecular profiling approach...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.912801/full |
| _version_ | 1811242291838320640 |
|---|---|
| author | Or Sehayek Waleed Kian Amir Onn Ronen Stoff Hadas Gantz Sorotsky Melanie Zemel Jair Bar Yulia Dudnik Hovav Nechushtan Yakir Rottenberg Lior Soussan-Gutman Addie Dvir Laila C. Roisman Nir Peled |
| author_facet | Or Sehayek Waleed Kian Amir Onn Ronen Stoff Hadas Gantz Sorotsky Melanie Zemel Jair Bar Yulia Dudnik Hovav Nechushtan Yakir Rottenberg Lior Soussan-Gutman Addie Dvir Laila C. Roisman Nir Peled |
| author_sort | Or Sehayek |
| collection | DOAJ |
| description | PurposeMolecular profiling is crucial in naïve non-small cell lung cancer (NSCLC). While tissue-based analysis is challenged by turnaround time and scarcity of tissue, there is increasing demand for liquid biopsy. We aimed to analyze the use of upfront liquid biopsy as a molecular profiling approach.MethodsThis retrospective multicenter, non-interventional study compared findings and turnaround times of liquid vs. standard-of-care (SOC) tissue-biopsy molecular profiling. The study included naïve advanced NSCLC patients with available liquid biopsy (Guardant360 CDx).ResultsA total of 42 consecutive patients (60% men; median age, 69.5 [39–87] years; 86% stage IV NSCLC) were identified between September 2017 and December 2020. Liquid-biopsy analysis provided results for all 42 patients, whereas the tissue-based analysis failed in 5 (12%) patients due to insufficient tumor samples. In 17 patients, 18 actionable driver mutations were identified. Eleven mutations were detected by both approaches (i.e., concordance of 61%), 4 only by liquid biopsy and 3 only by tissue biopsy. The median time from the molecular request to receiving the molecular solid report on the last biomarker was 21 (range: 5–66) days, whereas the median time from blood draw to the liquid-biopsy results was 10.5 (7–19) days. The median time between the availability of liquid-biopsy findings and that of the last biomarker was 5 days. Treatment changes following the liquid-biopsy results were observed in 3 (7%) patients.ConclusionPerforming liquid-biopsy upfront is feasible and accurate and allows a shorter time for treatment in NSCLC, especially when tumor tissue is scarce. |
| first_indexed | 2024-04-12T13:49:33Z |
| format | Article |
| id | doaj.art-85362ec588224779aae89838b8d19a1d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T13:49:33Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-85362ec588224779aae89838b8d19a1d2022-12-22T03:30:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.912801912801Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation SequencingOr Sehayek0Waleed Kian1Amir Onn2Ronen Stoff3Hadas Gantz Sorotsky4Melanie Zemel5Jair Bar6Yulia Dudnik7Hovav Nechushtan8Yakir Rottenberg9Lior Soussan-Gutman10Addie Dvir11Laila C. Roisman12Nir Peled13Ben-Gurion University, Be’er Sheva, IsraelThe Institute of Oncology, Shaare Zedek Medical Center, Jerusalem, IsraelSheba Medical Center, Ramat Gan, Israel, and Tel Aviv University Medical School, Tel Aviv, IsraelSheba Medical Center, Ramat Gan, Israel, and Tel Aviv University Medical School, Tel Aviv, IsraelSheba Medical Center, Ramat Gan, Israel, and Tel Aviv University Medical School, Tel Aviv, IsraelBen-Gurion University, Be’er Sheva, IsraelSheba Medical Center, Ramat Gan, Israel, and Tel Aviv University Medical School, Tel Aviv, IsraelSoroka Medical Center, Ben-Gurion University, Be’er Sheva, IsraelDepartment of Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelDepartment of Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelRhenium Oncotest Ltd., Modi’in, IsraelRhenium Oncotest Ltd., Modi’in, IsraelThe Institute of Oncology, Shaare Zedek Medical Center, Jerusalem, IsraelThe Institute of Oncology, Shaare Zedek Medical Center, Jerusalem, IsraelPurposeMolecular profiling is crucial in naïve non-small cell lung cancer (NSCLC). While tissue-based analysis is challenged by turnaround time and scarcity of tissue, there is increasing demand for liquid biopsy. We aimed to analyze the use of upfront liquid biopsy as a molecular profiling approach.MethodsThis retrospective multicenter, non-interventional study compared findings and turnaround times of liquid vs. standard-of-care (SOC) tissue-biopsy molecular profiling. The study included naïve advanced NSCLC patients with available liquid biopsy (Guardant360 CDx).ResultsA total of 42 consecutive patients (60% men; median age, 69.5 [39–87] years; 86% stage IV NSCLC) were identified between September 2017 and December 2020. Liquid-biopsy analysis provided results for all 42 patients, whereas the tissue-based analysis failed in 5 (12%) patients due to insufficient tumor samples. In 17 patients, 18 actionable driver mutations were identified. Eleven mutations were detected by both approaches (i.e., concordance of 61%), 4 only by liquid biopsy and 3 only by tissue biopsy. The median time from the molecular request to receiving the molecular solid report on the last biomarker was 21 (range: 5–66) days, whereas the median time from blood draw to the liquid-biopsy results was 10.5 (7–19) days. The median time between the availability of liquid-biopsy findings and that of the last biomarker was 5 days. Treatment changes following the liquid-biopsy results were observed in 3 (7%) patients.ConclusionPerforming liquid-biopsy upfront is feasible and accurate and allows a shorter time for treatment in NSCLC, especially when tumor tissue is scarce.https://www.frontiersin.org/articles/10.3389/fonc.2022.912801/fullcirculating tumor DNA (ctDNA)turnaround time (TAT)driver mutationliquid biopsynon-small cell lung carcinoma (NSCLC) |
| spellingShingle | Or Sehayek Waleed Kian Amir Onn Ronen Stoff Hadas Gantz Sorotsky Melanie Zemel Jair Bar Yulia Dudnik Hovav Nechushtan Yakir Rottenberg Lior Soussan-Gutman Addie Dvir Laila C. Roisman Nir Peled Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing Frontiers in Oncology circulating tumor DNA (ctDNA) turnaround time (TAT) driver mutation liquid biopsy non-small cell lung carcinoma (NSCLC) |
| title | Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing |
| title_full | Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing |
| title_fullStr | Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing |
| title_full_unstemmed | Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing |
| title_short | Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing |
| title_sort | liquid first is solid in naive non small cell lung cancer patients faster turnaround time with high concordance to solid next generation sequencing |
| topic | circulating tumor DNA (ctDNA) turnaround time (TAT) driver mutation liquid biopsy non-small cell lung carcinoma (NSCLC) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.912801/full |
| work_keys_str_mv | AT orsehayek liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT waleedkian liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT amironn liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT ronenstoff liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT hadasgantzsorotsky liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT melaniezemel liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT jairbar liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT yuliadudnik liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT hovavnechushtan liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT yakirrottenberg liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT liorsoussangutman liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT addiedvir liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT lailacroisman liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing AT nirpeled liquidfirstissolidinnaivenonsmallcelllungcancerpatientsfasterturnaroundtimewithhighconcordancetosolidnextgenerationsequencing |